α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation

α-radioimmunotherapy targeting CD45 may substitute for total-body irradiation in hematopoietic cell transplantation (HCT) preparative regimens for lymphoma. Our goal was to optimize the anti-CD45 monoclonal antibody (mAb; CA12.10C12) protein dose for 211At-radioimmunotherapy, extending the analysis to include intraorgan 211At activity distribution and α-imaging–based small-scale dosimetry, along with immunohistochemical staining. Methods: Eight normal dogs were injected with either a 0.75 (n = 5) or 1.00 (n = 3) mg/kg dose of 211At-B10-CA12.10C12 (11.5–27.6 MBq/kg). Two were euthanized and necropsied 19–22 h after injection, and 6 received autologous HCT 3 d after 211At-radioimmunotherapy, after lymph node and bone marrow biopsies at 2–4 and/or 19 h after injection. Blood was sampled to study toxicity and clearance; CD45 targeting was evaluated by flow cytometry. 211At localization and small-scale dosimetry were assessed using two α-imaging systems: an α-camera and an ionizing-radiation quantum imaging detector (iQID) camera. Results: 211At uptake was highest in the spleen (0.31–0.61% injected activity [%IA]/g), lymph nodes (0.02–0.16 %IA/g), liver (0.11–0.12 %IA/g), and marrow (0.06–0.08 %IA/g). Lymphocytes in blood and marrow were efficiently targeted using either mAb dose. Lymph nodes remained unsaturated but displayed targeted 211At localization in T lymphocyte–rich areas. Absorbed doses to blood, marrow, and lymph nodes were estimated at 3.1, 2.4, and 3.4 Gy/166 MBq, respectively. All transplanted dogs experienced transient hepatic toxicity. Liver enzyme levels were temporarily elevated in 5 of 6 dogs; one treated with 1.00 mg mAb/kg developed ascites and was euthanized 136 d after HCT. Conclusion: 211At-anti-CD45 radioimmunotherapy with 0.75 mg mAb/kg efficiently targeted blood and marrow without severe toxicity. Dosimetry calculations and observed radiation-induced effects indicated that sufficient 211At-B10-CA12.10C12 localization was achieved for efficient conditioning for HCT.

[1]  Lloyd H. Michael,et al.  The Guide for the Care and Use of Laboratory Animals. , 2016, ILAR journal.

[2]  Harrison H Barrett,et al.  The iQID camera: An ionizing-radiation quantum imaging detector. , 2014, Nuclear instruments & methods in physics research. Section A, Accelerators, spectrometers, detectors and associated equipment.

[3]  L. V. van Vliet,et al.  Additional Diagnostic Value of Integrated Analysis of Cardiac CTA and SPECT MPI Using the SMARTVis System in Patients with Suspected Coronary Artery Disease , 2014, The Journal of Nuclear Medicine.

[4]  Lanjuan Li,et al.  Human Hepatic Progenitor Cells Express Hematopoietic Cell Markers CD45 and CD109 , 2013, International journal of medical sciences.

[5]  P. Albertsson,et al.  Ex Vivo Activity Quantification in Micrometastases at the Cellular Scale Using the α-Camera Technique , 2013, The Journal of Nuclear Medicine.

[6]  B. Sandmaier,et al.  Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines. , 2012, Bioconjugate chemistry.

[7]  R. Storb,et al.  Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. , 2012, Blood.

[8]  L. Jacobsson,et al.  The α-Camera: A Quantitative Digital Autoradiography Technique Using a Charge-Coupled Device for Ex Vivo High-Resolution Bioimaging of α-Particles , 2010, The Journal of Nuclear Medicine.

[9]  R. Storb,et al.  Pilot Study of a 213Bismuth-Labeled Anti-CD45 mAb as a Novel Nonmyeloablative Conditioning for DLA-Haploidentical Littermate Hematopoietic Transplantation , 2010, Transplantation.

[10]  B. Wessels,et al.  MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy* , 2010, Journal of Nuclear Medicine.

[11]  G. Kanel,et al.  Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells after liver injury. , 2009, Gastroenterology.

[12]  R. Storb,et al.  Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211. , 2009, Cancer research.

[13]  Amin I Kassis,et al.  Therapeutic radionuclides: biophysical and radiobiologic principles. , 2008, Seminars in nuclear medicine.

[14]  D. Maloney,et al.  Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. , 2007, Blood.

[15]  M. Brechbiel,et al.  Radioimmunotherapy with Bismuth-213 as Conditioning for Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Dogs: A Dose Deescalation Study , 2004, Transplantation.

[16]  J. Rasko,et al.  The Biology of CD45 and its Use as a Therapeutic Target , 2004, Leukemia & lymphoma.

[17]  R. Vessella,et al.  Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds. , 2004, Bioconjugate chemistry.

[18]  M. Brechbiel,et al.  Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. , 2002, Blood.

[19]  K. Magnusson,et al.  Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats , 1996, Hepatology.

[20]  R. Storb,et al.  MARROW GRAFTS BETWEEN DL‐A‐MATCHED CANINE LITTERMATES , 1973, Transplantation.

[21]  R. Storb,et al.  Marrow infusions in dogs given midlethal or lethal irradiation. , 1970, Radiation research.

[22]  M. Michaelson,et al.  Plasma, erythrocyte, and whole blood volume in the normal beagle. , 1968, American journal of veterinary research.